Nanoscopic tau aggregates in Parkinson’s disease

Le résumé fourni par la source

Abstract Post-mortem tau pathology is frequently observed in Parkinson’s disease (PD) using immunohistochemistry (IHC) to measure large inclusions. However, small protein aggregates that precede inclusions are considered a major driver of toxicity in neurodegenerative disease. We aimed to uncover the distribution of nanoscopic aggregates across six brain regions in post-mortem tissue from 14 PD cases, 7 cases with age-related tau deposition, and 8 neuropathology-free controls using the single-molecule pull-down assay (SiMPull). In the hippocampus and amygdala, tau aggregates were detected by SiMPull that correlated with tau IHC immunostaining. Despite negligible IHC-labelled aggregates in the putamen, we identified a population of high-intensity nanoscopic tau aggregates in PD using SiMPull, labelled by 10–1000 antibodies per aggregate and 30–800 nm in length. Nanoscopic tau aggregate burden in PD resembled mid-Braak-stage Alzheimer’s disease and appeared to precede inclusions. Meanwhile, SiMPull did not detect a PD-specific population of nanoscopic αSyn aggregates, and instead detected low-order multimers. Finally, tau aggregation was associated with Lewy Body load and dementia status in PD.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.